Stay updated on Tazemetostat + Pembrolizumab in Urothelial Carcinoma Clinical Trial
Sign up to get notified when there's something new on the Tazemetostat + Pembrolizumab in Urothelial Carcinoma Clinical Trial page.

Latest updates to the Tazemetostat + Pembrolizumab in Urothelial Carcinoma Clinical Trial page
- Check2 days agoNo Change Detected
- Check10 days agoNo Change Detected
- Check17 days agoChange DetectedA newer revision label (v3.6.5) is shown, indicating a site update; the core study information remains unchanged.SummaryDifference0.0%

- Check24 days agoChange DetectedThe study record now lists UPMC Hillman Cancer Center as a participating site, replacing University of Pittsburgh Cancer Institute (UPCI). This reflects an organizational naming update and a new revision of the study record (v3.6.4).SummaryDifference0.2%

- Check52 days agoChange DetectedRevision updated from v3.6.2 to v3.6.3. This signifies a new page version for maintenance or updates, without changing the substantive study information.SummaryDifference0.0%

- Check59 days agoChange DetectedRevision tag updated from v3.6.0 to v3.6.2, indicating a maintenance update to the page. This change does not alter the study details, eligibility criteria, or outcomes presented on the page.SummaryDifference0.0%

- Check74 days agoChange DetectedThe page now indicates that recruitment has ended (No longer looking for participants). New help/navigation sections were added (How to Read a Study Record, Common Questions, How to Join a Study) and the Intervention/Treatment heading was revised.SummaryDifference0.8%

- Check81 days agoChange DetectedRevision: v3.5.5 was added, replacing v3.5.4. This reflects a routine site update that does not alter the study details or page content.SummaryDifference0.0%

Stay in the know with updates to Tazemetostat + Pembrolizumab in Urothelial Carcinoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Tazemetostat + Pembrolizumab in Urothelial Carcinoma Clinical Trial page.